Prometheus Biosciences to Participate at November Healthcare Conferences
Get Alerts RXDX Hot Sheet
Join SI Premium – FREE
SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will conduct fireside chats at the following healthcare conferences:
Credit Suisse Annual Healthcare ConferenceDate: Tuesday, November 8, 2022Time: 12:50 pm EST
Guggenheim 4th Annual Immunology and Neurology ConferenceDate: Tuesday, November 15, 2022Time: 11:20 am EST
Jefferies London Healthcare ConferenceDate: Thursday, November 17, 2022Time: 9:10 am GMT
A live and archived webcast of the fireside chats will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website.
About Prometheus Biosciences
Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The Company’s precision medicine platform, Prometheus360TM, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.
About PRA023: Pipeline in a Product Candidate
The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A). PRA023 binds both soluble and membrane-associated human TL1A with high affinity and specificity and has the potential to substantially improve outcomes for moderate-to-severe IBD patients predisposed to increased TL1A expression. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis (UC), Crohn’s Disease (CD), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
The Company is currently conducting three Phase 2 studies of PRA023: a Phase 2 trial in UC patients, ARTEMIS-UC, a Phase 2a trial in CD patients, APOLLO-CD, and a Phase 2 trial in SSc-ILD, ATHENA-SSc-ILD, each utilizing a genetic-based companion diagnostic candidate designed to identify patients who are predisposed to increased expression of TL1A and therefore potentially more likely to respond to PRA023.
Prometheus Biosciences Contact:Noel KurdiVP Investor Relations and Communications(646) 241-4400[email protected]
Media contact:Juniper PointAmy Conrad(858) 914-1962[email protected]
Source: Prometheus BiosciencesSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Check Point Software Reports 2024 First Quarter Financial Results
- Šiaulių Bankas invitation to Q1 2024 Financial Results webinar
- New Report Pins 6G Success on Novel Benchmarks Extending Beyond Speed, Latency, and Mobility
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Credit Suisse, Jefferies & Co, GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!